Pharmacosmos

CompanyDenmarkFounded 1965

RORWikidata

Pharmacosmos develops 7 assets, the furthest approved (Ferric Derisomaltose in Anemia, Iron-Deficiency). Mostly small molecule and other acting on CDK6 and CDK4; based in Denmark, founded in 1965.

7
Assets
Furthest stage
Approved
31
Trials
8
Signals

Pipeline

7
  • Ferric Derisomaltose

    Replenishes iron stores to correct iron deficiency and support oxygen transport and cellular energy metabolism.

    Approved, Other, Anemia, Iron-Deficiency, iron deficiency (Phase 3)

  • Trilaciclib

    Transiently inhibits CDK4/6 to protect hematopoietic stem and progenitor cells from chemotherapy-induced damage.

    Approved, Small molecule, CDK6, CDK4, myelosuppression, extensive stage small cell lung cancer (Phase 3)

  • Petadeferitrin

    Chelates iron to treat transfusional iron overload.

    Phase 2, Small molecule, transfusion-dependent thalassemia, transfusional iron overload

4 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms4
  • Trials43
  • People17
  • Signals18
  • Similar companies6

Papers

Intelligence